Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The only curative option for pancreatic cancer patients is surgery, but the patients within
20% of them are possible for a radical surgery. Accordingly, concurrent chemo-radiation
therapy is generally used for palliation of unresectable pancreatic cancer patients. So far,
the use of 5-fluorouracil (5-FU) was the traditional method of chemotherapy. However, these
days, oral anti-cancer medicine, capecitabine(Xeloda®), was developed and considered as an
alternative medicine of 5-fluorouracil (5-FU). Furthermore, according to the recent results
of clinical trials, the clinical use of capecitabine(Xeloda®) with radiation therapy was
proved to be very effective and safe. The purpose of this trial is to improve the therapeutic
effects by using proton therapy and chemotherapy concurrently.